Beta amyloid peptide plaques fail to alter evoked neuronal calcium signals in APP/PS1 Alzheimer's disease mice

Neurobiology of Aging

Volumn 34, Issue 6, 2013, Pages 1632-1643

  Briggs, Clark A ^a   Schneider, Corinne ^a   Richardson, Jill C ^b   Stutzmann, Grace E ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

2 photon imaging; Alzheimer's disease; Beta amyloid protein; Calcium signaling; Hippocampus; Patch clamp; Transgenic mice

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CALCIUM; DIRECT YELLOW 7; DYE; PRESENILIN 1; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CALCIUM SIGNALING; CALCIUM TRANSPORT; CONTROLLED STUDY; DENDRITE; DISEASE EXACERBATION; EVOKED RESPONSE; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; FLUORESCENCE IMAGING; HIPPOCAMPUS; IMAGING AND DISPLAY; INTRACELLULAR RECORDING; MALE; MOUSE; NERVE POTENTIAL; NEUROPATHOLOGY; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RECEPTOR UPREGULATION; TWO PHOTON IMAGING; WHOLE CELL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CALCIUM SIGNALING; EXCITATORY POSTSYNAPTIC POTENTIALS; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; PLAQUE, AMYLOID; PRESENILIN-1;

EID: 84875254177     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.12.013     Document Type: Article

References (76)

1. Aho L., Pikkarainen M., Hiltunen M., Leinonen V., Alafuzoff I. Immunohistochemical visualization of amyloid-β protein precursor and amyloid-β in extra- and intracellular compartments in the human brain. J. Alzheimers Dis. 2010, 20:1015-1028.
2. Aisen P.S., Andrieu S., Sampaio C., Carrillo M., Khachaturian Z.S., Dubois B., Feldman H.H., Petersen R.C., Siemers E., Doody R.S., Hendrix S.B., Grundman M., Schneider L.S., Schindler R.J., Salmon E., Potter W.Z., Thomas R.G., Salmon D., Donohue M., Bednar M.M., Touchon J., Vellas B. Report of the task force on designing clinical trials in early (predementia) AD. Neurology 2011, 76:280-286.
3. Arnold S.E., Louneva N., Cao K., Wang L.S., Han L.Y., Wolk D.A., Negash S., Leurgans S.E., Schneider J.A., Buchman A.S., Wilson R.S., Bennett D.A. Cellular, synaptic, and biochemical features of resilient cognition in Alzheimer's disease. Neurobiol. Aging 2013, 34:157-168.
4. Arriagada P.V., Marzloff K., Hyman B.T. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992, 42:1681-1688.
5. Auffret A., Mariani J., Rovira C. Age-related progressive synaptic dysfunction: the critical role of presenilin 1. Rev. Neurosci. 2010, 21:239-250.
6. Benilova I., Karran E., De Strooper B. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 2012, 15:349-357.
7. Berridge M.J. Calcium hypothesis of Alzheimer's disease. Pflugers Arch. 2010, 459:441-449.
8. Bezprozvanny I. Calcium signaling and neurodegenerative diseases. Trends Mol. Med. 2009, 15:89-100.
9. Bodhinathan K., Kumar A., Foster T.C. Redox sensitive calcium stores underlie enhanced after hyperpolarization of aged neurons: role for ryanodine receptor mediated calcium signaling. J. Neurophysiol. 2010, 104:2586-2593.
10. Bouchard R., Pattarini R., Geiger J.D. Presence and functional significance of presynaptic ryanodine receptors. Prog. Neurobiol. 2003, 69:391-418.
11. Bull R., Finkelstein J.P., Humeres A., Behrens M.I., Hidalgo C. Effects of ATP, Mg2+, and redox agents on the Ca2+ dependence of RyR channels from rat brain cortex. Am. J. Physiol Cell Physiol. 2007, 293:C162-C171.
12. Busche M.A., Chen X., Henning H.A., Reichwald J., Staufenbiel M., Sakmann B., Konnerth A. Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:8740-8745.
13. Busche M.A., Eichhoff G., Adelsberger H., Abramowski D., Wiederhold K.H., Haass C., Staufenbiel M., Konnerth A., Garaschuk O. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science 2008, 321:1686-1689.
14. Bussiere T., Bard F., Barbour R., Grajeda H., Guido T., Khan K., Schenk D., Games D., Seubert P., Buttini M. Morphological characterization of thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Aβ immunotherapy on their clearance. Am. J. Pathol. 2004, 165:987-995.
15. Camandola S., Mattson M.P. Aberrant subcellular neuronal calcium regulation in aging and Alzheimer's disease. Biochim. Biophys. Acta 2011, 1813:965-973.
16. Castellani R.J., Smith M.A. Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is 'too big to fail'. J. Pathol. 2011, 224:147-152.
17. Chakroborty S., Goussakov I., Miller M.B., Stutzmann G.E. Deviant ryanodine receptor-mediated calcium release resets synaptic homeostasis in presymptomatic 3xTg-AD mice. J. Neurosci. 2009, 29:9458-9470.
18. Chakroborty S., Kim J., Schneider C., Jacobson C., Molgó J., Stutzmann G.E. Early pre- and postsynaptic calcium signaling abnormalities mask underlying synaptic depression in presymptomatic Alzheimer's disease mice. J. Neurosci. 2012, 32:8341-8353.
19. Chakroborty S., Stutzmann G.E. Early calcium dysregulation in Alzheimer's disease: setting the stage for synaptic dysfunction. Sci. China Life Sci. 2011, 54:752-762.
20. Chasseigneaux S., Allinquant B. Functions of Aβ, sAPPα and sAPPβ: similarities and differences. J. Neurochem. 2012, 120(Suppl 1):99-108.
21. Clare R., King V.G., Wirenfeldt M., Vinters H.V. Synapse loss in dementias. J. Neurosci. Res. 2010, 88:2083-2090.
22. Demuro A., Parker I., Stutzmann G.E. Calcium signaling and amyloid toxicity in Alzheimer disease. J. Biol. Chem. 2010, 285:12463-12468.
23. Disterhoft J.F., Oh M.M. Alterations in intrinsic neuronal excitability during normal aging. Aging Cell 2007, 6:327-336.
24. 2+ release channels in neurological diseases. Pflugers Arch. 2010, 460:481-494.
25. Foster T.C. Calcium homeostasis and modulation of synaptic plasticity in the aged brain. Aging Cell 2007, 6:319-325.
26. Galimberti D., Scarpini E. Disease-modifying treatments for Alzheimer's disease. Ther. Adv. Neurol. Disord. 2011, 4:203-216.
27. 2+-dysregulation aging phenotype in hippocampal neurons. J. Neurosci. 2011, 31:1693-1703.
28. Ghosh D., LeVault K.R., Barnett A.J., Brewer G.J. A reversible early oxidized redox state that precedes macromolecular ROS damage in aging nontransgenic and 3xTg-AD mouse neurons. J Neurosci. 2012, 32:5821-5832.
29. Gibson G.E., Starkov A., Blass J.P., Ratan R.R., Beal M.F. Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. Biochim. Biophys. Acta 2010, 1802:122-134.
30. Goate A., Hardy J. Twenty years of Alzheimer's disease-causing mutations. J. Neurochem. 2012, 120:3-8.
31. Goldman W.P., Price J.L., Storandt M., Grant E.A., McKeel D.W., Rubin E.H., Morris J.C. Absence of cognitive impairment or decline in preclinical Alzheimer's disease. Neurology 2001, 56:361-367.
32. 2+ oscillations as a consequence of altered ryanodine receptor function in AD neurons. Channels (Austin) 2011, 5:9-13.
33. 2+ influx drives aberrant ryanodine receptor activation in dendrites of young Alzheimer's disease mice. J. Neurosci. 2010, 30:12128-12137.
34. Guo Q., Wang Z., Li H., Wiese M., Zheng H. APP physiological and pathophysiological functions: insights from animal models. Cell Res. 2012, 22:78-89.
35. Hidalgo C., Donoso P., Carrasco M.A. The ryanodine receptors Ca2+ release channels: cellular redox sensors?. IUBMB. Life 2005, 57:315-322.
36. Hermes M., Eichhoff G., Garaschuk O. Intracellular calcium signalling in Alzheimer's disease. J. Cell. Mol. Med. 2010, 14:30-41.
37. Herrup K. Reimagining Alzheimer's disease - an age-based hypothesis. J. Neurosci. 2010, 30:16755-16762.
38. Holtzman D.M., Morris J.C., Goate A.M. Alzheimer's disease: the challenge of the second century. Sci. Transl. Med. 2011, 3:77sr1.
39. Howlett D.R., Richardson J.C., Austin A., Parsons A.A., Bate S.T., Davies D.C., Gonzalez M.I. Cognitive correlates of Aβ deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res. 2004, 1017:130-136.
40. Itkin A., Dupres V., Dufrêne Y.F., Bechinger B., Ruysschaert J.M., Raussens V. Calcium ions promote formation of amyloid β-peptide(1-40) oligomers causally implicated in neuronal toxicity of Alzheimer's Disease. PLoS One 2011, 6:e18250.
41. Karran E., Mercken M., De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 2011, 10:698-712.
42. Kazee A.M., Johnson E.M. Alzheimer's Disease pathology in non-demented elderly. J. Alzheimers Dis. 1998, 1:81-89.
43. Kuchibhotla K.V., Goldman S.T., Lattarulo C.R., Wu H.Y., Hyman B.T., Bacskai B.J. Aβ plaques lead to aberrant regulation of calcium homeostasis In vivo resulting in structural and functional disruption of neuronal networks. Neuron 2008, 59:214-225.
44. Kuchibhotla K.V., Lattarulo C.R., Hyman B.T., Bacskai B.J. Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science 2009, 323:1211-1215.
45. Kumar A., Bodhinathan K., Foster T.C. Susceptibility to calcium dysregulation during brain aging. Front. Aging Neurosci. 2009, 1:2.
46. Larson M.E., Lesne S.E. Soluble Aβ oligomer production and toxicity. J. Neurochem. 2012, 120(Suppl 1):125-139.
47. Lazarov O., Peterson L.D., Peterson D.A., Sisodia S.S. Expression of a familial Alzheimer's disease-linked presenilin-1 variant enhances perforant pathway lesion-induced neuronal loss in the entorhinal cortex. J. Neurosci. 2006, 26:429-434.
48. Minkeviciene R., Banerjee P., Tanila H. Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. J. Pharmacol. Exp. Ther. 2004, 311:677-682.
49. 2+ signaling. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:13293-13298.
50. 2+ signaling. Antioxid. Redox. Signal. 2011, 14:1225-1235.
51. Oh M.M., Oliveira F.A., Disterhoft J.F. Learning and aging related changes in intrinsic neuronal excitability. Front. Aging Neurosci. 2010, 3:2.
52. Palop J., Mucke L. Synaptic depression and aberrant excitatory network activity in Alzheimer's disease: two faces of the same coin?. Neuromolecular Med. 2010, 12:48-55.
53. Penzes P., Cahill M.E., Jones K.A., VanLeeuwen J.E., Woolfrey K.M. Dendritic spine pathology in neuropsychiatric disorders. Nat. Neurosci. 2011, 14:285-293.
54. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010, 362:329-344.
55. Sadowski M., Pankiewicz J., Scholtzova H., Ji Y., Quartermain D., Jensen C.H., Duff K., Nixon R.A., Gruen R.J., Wisniewski T. Amyloid-β deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice. J. Neuropathol. Exp. Neurol. 2004, 63:418-428.
56. Scheff S.W., Price D.A. Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol. Aging 2003, 24:1029-1046.
57. Scheff S.W., Price D.A. Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus. J. Alzheimers Dis. 2006, 9:101-115.
58. Schmitt F.A., Davis D.G., Wekstein D.R., Smith C.D., Ashford J.W., Markesbery W.R. " Preclinical" AD revisited: neuropathology of cognitively normal older adults. Neurology 2000, 55:370-376.
59. Selkoe D.J. Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci. 1993, 16:403-409.
60. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
61. Selkoe D.J. Alzheimer's disease. Cold Spring Harb. Perspect. Biol. 2011, 3:a004457.
62. Selkoe D.J. Resolving controversies on the path to Alzheimer's therapeutics. Nat. Med. 2011, 17:1060-1065.
63. 2+ leak channels. J. Biol. Chem. 2012, 287:10933-10944.
64. Spires-Jones T., Knafo S. Spines, plasticity, and cognition in Alzheimer's model mice. Neural Plast. 2012, 2012:319836.
65. Stone J.G., Casadesus G., Gustaw-Rothenberg K., Siedlak S.L., Wang X., Zhu X., Perry G., Castellani R.J., Smith M.A. Frontiers in Alzheimer's disease therapeutics. Ther. Adv. Chronic Dis. 2011, 2:9-23.
66. Stutzmann G.E. The pathogenesis of Alzheimers disease: is it a lifelong " calciumopathy" ?. Neuroscientist 2007, 13:546-559.
67. 2+ handling in excitable cells in health and disease. Pharmacol. Rev. 2011, 63:700-727.
68. Stutzmann G.E., Parker I. Dynamic multiphoton imaging: a live view from cells to systems. Physiology (Bethesda) 2005, 20:15-21.
69. 2+ disruptions in young, adult, and aged Alzheimer's disease mice. J. Neurosci. 2006, 26:5180-5189.
70. Supnet C., Bezprozvanny I. Presenilins function in ER calcium leak and Alzheimer's disease pathogenesis. Cell Calcium 2011, 50:303-309.
71. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991, 30:572-580.
72. Thibault O., Gant J.C., Landfield P.W. Expansion of the calcium hypothesis of brain aging and Alzheimer's disease: minding the store. Aging Cell 2007, 6:307-317.
73. Thibault O., Pancani T., Landfield P.W., Norris C.M. Reduction in neuronal L-type calcium channel activity in a double knock-in mouse model of Alzheimer's disease. Biochim. Biophys. Acta 2012, 1822:546-549.
74. Waters J. The concentration of soluble extracellular amyloid-β protein in acute brain slices from CRND8 mice. PLoS One 2010, 5:e15709.
75. Wykes R., Kalmbach A., Eliava M., Waters J. Changes in the physiology of CA1 hippocampal pyramidal neurons in preplaque CRND8 mice. Neurobiol. Aging 2012, 33:1609-1623.
76. Zhang H., Ma Q., Zhang Y.W., Xu H. Proteolytic processing of Alzheimer's β-amyloid precursor protein. J. Neurochem. 2012, 120(Suppl 1):9-21.